| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10309070 | Schizophrenia Research | 2013 | 8 Pages |
Abstract
Twelve months of treatment with lurasidone met noninferiority criteria, and was associated with higher rates of remission, and reduced risk of hospitalization compared with QXR. No clinically significant effects on weight or metabolic parameters were observed during maintenance treatment with lurasidone.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Antony Loebel, Josephine Cucchiaro, Jane Xu, Kaushik Sarma, Andrei Pikalov, John M. Kane,